H. Mei

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myeloma, without leukapheresis and lymphodeple...

Belumosudil for acute GVHD after allogeneic hematopoietic stem cell transplantation: a retrospective case series.

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1

Bispecific antibodies have gradually been applied in the treatment of multiple myeloma(MM). The combination of bispecific antibodies targeting CD3 and CD28 mimics the dual-signaling system (antigen signaling and co-stimulatory signaling) of natural T cell activation, thereby significantly enhancing the anti-tumor res...

High IL‐10 levels during CRS are negatively associated with NK‐cell recovery after CAR‐T cell therapy

Findings highlight a previously underappreciated role of IL‐10 in shaping NK‐cell reconstitution post‐CAR‐T cell therapy, particularly in the setting of CRS, which may benefit patients with CRS accompanied by elevated IL‐10 levels.